Business Context and Reporting Period
This Form 8-K is a Current Report filed by NanoVibronix, Inc. (trading symbol: NAOV) on December 4, 2025. The filing reports on the results of the Company's Annual Meeting of Stockholders held on the same date. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Corporate Actions
- Board Composition Changes: Four directors (Christopher Fashek, Thomas Mika, Martin Goldstein, M.D., and Brian Murphy) retired effective immediately prior to the Annual Meeting. Their departures were for personal reasons and not due to disagreements with the Company.
- Election of New Directors: Stockholders elected five new directors to serve one-year terms: Doron Besser, M.D., David Johnson, Zeev Rotstein, M.D., Nino Pionati, and Alison Geiger Burgett.
- Equity Plan Amendment: Stockholders approved the First Amendment to the 2024 Long-Term Incentive Plan, increasing the number of shares available for issuance by 1,200,000 to a total of 1,205,454 shares.
- Capital Structure Approval: Stockholders approved the issuance of shares underlying convertible preferred stock and warrants from a July 2025 private placement, which may exceed 19.99% of pre-issuance outstanding common stock, to comply with Nasdaq Listing Rule 5635(d).
- Auditor Ratification: Kost Forer Gabbay & Kasierer (Ernst & Young Global) was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosures regarding the adjournment proposal. The Adjournment Proposal was approved but not utilized as the meeting did not require adjournment.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the retirement of four members and election of five new members.
- Review the terms of the First Amendment to the 2024 Long-Term Incentive Plan (Exhibit 10.1) to understand the impact of the 1,200,000 share increase on future dilution.
- Confirm the details of the July 2025 private placement and the specific terms of the convertible preferred stock and warrants approved under Proposal 4.
- Check the voting results for Proposal 3 (Incentive Plan) and Proposal 4 (Issuance), which received lower "For" vote counts compared to other proposals, indicating potential shareholder scrutiny on equity dilution.